Tags : Immune Tolerance Therapy


Pfizer Exercised its Option to License AnTolRx’s Immune Tolerance Therapy

Shots: Pfizer to get exclusive rights for development and commercialization of AnTolRx’s lead immunotherapeutic for T1D. AnTolRx to receive upfront, milestones & royalties on sales Under the June 2016 agreement, Pfizer exercised its option to license AnTolRx’s T1D candidate AnTolRx develops antigen-specific therapies, based on immune tolerance induction, for inflammatory and autoimmune diseases including T1D, […]Read More